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The goal of research in transplant therapeutics is to achieve
safe and effective immunosuppression strategies that allow
durable engraftment free of toxicities. The calcineurin
inhibitors (CNIs) regimens, because of their inherent toxicities
(including nephrotoxicity), have been unable to meet these
promises. Over the past decade acute cellular rejection
decreased dramatically with a concomitant robust increase in
1-year graft survival; however, long-term graft outcome
showed only modest improvement. This is due in part to the
toxicities of the immunosuppressive drugs. The quest for a
toxicity-free–CNI-free regimen has been both intense and
frustrating. A turning point in CNIs-free therapy may have
occurred with the recent approval of belatacept, which
represents a new paradigm in immunosuppression:
biological therapy for chronic immunosuppression devoid
of the usual toxicities associated with the CNIs. Belatacept,
a fusion receptor protein, blocks costimulation signals
necessary for the activation of T cells. Although costimulation
blockade has not been shown to induce tolerance, it can
provide safe and effective immunosuppression without renal
or cardiovascular toxicities. The approval of belatacept in
both the United States and Europe for use in renal
transplantation will finally push CNI-free regimens into prime
time. Novel biologics such as ASKP1240 (a human anti-CD40
monoclonal antibody) and one small molecule, tofacitinib,
may advance further the use of CNI-free regimens in organ
transplantation.
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The introduction of cyclosporine in the 1980s transformed
the field of transplantation in ways that few would have
foreseen.1 The dramatic improvement in outcome of patients
treated with cyclosporine established renal transplantation as
the treatment of choice for the patients with end-stage renal
disease. The addition of tacrolimus and the more potent
antiproliferative agents mycophenolate mofetil (MMF) and
sirolimus, as well as biological induction, depleting anti-
bodies, and anti-IL2 receptor monoclonals, led to greater
efficacy, lower rate of acute complications, and shorter
hospital stays.2–5 These novel potent immunosuppression
regimens introduced in the 90s reduced acute rejection to
levels below 20% and produced substantial gains in 1-year
graft survival.3,4 The spectacular success of calcineurin
inhibitor (CNI)–based regimens had, however, a dark side
that continues to limit better longer-term patient and graft
survival. It has been amply documented that the reduction of
acute rejection did not appreciably improve patient and graft
outcome beyond the first year of transplantation.3,4 In fact in
over 50,000 kidney transplant recipients analyzed by the
Collaboration Transplant Study, any combination of CNIs
and antiproliferatives resulted in exactly the same graft
survival at 5 years.6
Table 1 lists five potential reasons for the failure of CNI-
based regimens to improve long-term outcome. Even the role
of the nephrotoxicity of CNIs as an important cause of graft
failure has become a controversial issue. That CNIs are and
can be nephrotoxic and that they can induce progressive renal
failure is undisputed.7,8 However, their previously documen-
ted prominent role in late graft dysfunction has recently been
questioned.9,10 The progressive and inexorable nature of CNI
nephrotoxicity was documented in an elegant study by
Nankivell et al. in renal allografts biopsied yearly over 10-year
follow-up. However, a critique of this study is that analysis of
donor-specific antibodies (DSAs) and C4d staining were not
available at the time the study was conducted, and that the
diagnosis of nephrotoxicity is not specific and thus assigning
the cause of the histological findings may not have been
precise. In fact, three recent histological analyses dispute the
conclusions by Nankivell et al. Cosio et al. in a study of
protocol kidney biopsies performed at 1 year in low
immunological risk recipients reported that the presence of
histological abnormalities usually ascribed to CNIs (tubular
atrophy and interstitial fibrosis) were not associated with
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progressive renal dysfunction.9 Instead the finding of
inflammation in the biopsies adversely affected subsequent
renal function. In a study by Snanoudj et al.,11 histological
lesions associated with CNI toxicity were present, though less
frequently, in kidneys of patients who were never exposed to
CNIs. In the multicenter DEKAF (Determination of Late
Kidney Failure) trial, transplant recipients who had been
assigned a histological diagnosis of CNI nephrotoxicity had
better outcome than those without it. The interpretation of
these data is not that CNI toxicity is necessarily benign, but
that if patients have enough CNI exposure to produce
nephrotoxicity, they also may have been optimally immuno-
suppressed. Furthermore, in the DEKAF trial, chronic
antibody–mediated rejection (diagnosed by DSA or C4d or
both) and not nephrotoxicity was the predominant cause of
late graft dysfunction. The conclusion from the DEKAF trial
and the study by Cosio et al. is that alloimmune injury (from
under-immunosuppression) rather than nephrotoxicity
(from elevated exposure to CNIs) may be the primary cause
of late graft failure. This would imply that strategies that were
advocated to minimize CNI exposure to decrease nephro-
toxicity and to improve renal function in the short term may
have the unintended consequence of increasing the risk of
chronic rejection and accelerate the loss of renal allo-
grafts.12,13 The need for CNI-free regimens has become more
urgent yet it has remained elusive.14,15 Withdrawal of CNIs
after a period of time after transplantation and conversion to
a CNI-free regimen have been attempted with mixed
results.16 Even the combination of Tor inhibitors and
mycophenolic acid after CNI withdrawal is challenging both
in terms of efficacy and toxicity.12,15
CNI-FREE REGIMENS WITH COSTIMULATION BLOCKADE
A more direct approach has been to attempt a CNI-free
regimen de novo after transplantation. One of the earliest
multicenter trials combined prolonged anti-IL2 receptor
antibody therapy with daclizumab, MMF, and steroids.14
This immunosuppression strategy was associated with an
unacceptably high rate of acute rejection although the 1-year
patient and graft survival was good. The introduction of Tor
inhibitors added a new element to this approach, leading to
combined use of the antiproliferatives sirolimus and MMF
as replacements of the CNIs. Although early results were
encouraging, larger randomized trials failed to show
satisfactory efficacy and tolerability of this regimen.12,15,17
Thus, new agents that inhibit novel and critical pathways of
immune activation are needed for the acceptance of CNI-free
regimens in clinical practice.
Three agents in clinical trials may help fulfill the promise
of non-nephrotoxic, safe, and effective immunosuppression
(Table 2). The first agent is belatacept produced by Bristol-
Myers Squibb and approved for use in transplantation in
both the United States and Europe in 2011. Belatacept
represents a novel paradigm in immunosuppression. It is a
biological agent, a fusion receptor protein that is adminis-
tered intravenously for chronic immunosuppression and
developed as a replacement of the CNIs.18,19 The scientific
rationale for the therapeutic inhibition of the costimulation
pathway with agents such as abatacept (CTLA4Ig) for
rheumatoid arthritis and belatacept for transplantation has
been a cornerstone basic of research in immunology and is
the culmination of experimental investigations for over a
quarter of a century20,21 (Figures 1 and 2).
Following alloantigen stimulation through the T-cell
receptor (signal one), the T cell requires a second signal
through the costimulatory pathways for full activation. The
binding by the CD28 first to CD86 and then to CD80 results
in the activation and proliferation of T cells. Belatacept, a
second-generation CTLA4Ig, binds with high affinity to the
CD86/CD80 and inhibits delivery of costimulatory signals
through the CD28 receptor leading to T-cell anergy. In a
phase II trial and two pivotal phase III trials (BENEFIT for
recipients of kidneys from standard deceased and living
donors and BENEFIT-EXT for recipients of kidneys from
extended-criteria donors), two regimens (a more intense and
less intense dosing schedule) of belatacept were used in
combination with MMF and steroids.22–24 The less intense
regimen was approved for use by the Food and Drug
Table 2 | Novel agents to replace CNIs
Agent Mechanism of action Formulation Status
Belatacept Costimulation blockade Fusion-receptor protein for i.v.
administration
Approved for use in renal transplantation in 2011
Tofacitinib Inhibits JAK3 signaling pathway Small molecule in pill form Phase IIb completed; phase III in RA completed
with possible approval in 2012 for RA
ASKP1240 Fully human anti-CD40 mAb Biological for i.v. administration Phase I in renal transplantation-completed
Abbreviations: CNIs, calcineurin inhibitors; i.v., intravenous; mAb, monoclonal antibody; RA, rheumatoid arthritis.
Table 1 | Five important reasons for the failure of
CNI-based regimens to improve long-term outcome
1. Early cellular rejection, decreased by the CNIs, does not impact long-
term graft survival
2. Immunosuppression with CNIs may be inadequate in controlling the
emergence of DSA and chronic antibody–mediated rejection, a major
cause of late graft failure either because of minimization regimens and/
or non-adherence
3. Late graft failure may occur from mechanisms unrelated to alloimmune
injury: nephrotoxicity, accelerated senescence, and glomerular disease
4. Graft loss from BK nephropathy
5. Persistence of graft loss from premature death from infections and
cardiovascular disease
Abbreviation: BK, polyomavirus; CNIs, calcineurin inhibitors.
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Administration because it was as effective as cyclosporine and
provided a better safety profile than the more intense
regimen (Figure 3). The 3-year outcome of patients treated
with the lower intensity regimen of belatacept vs. cyclospor-
ine in the phase III trials are shown in Table 3.
Although there were more cases of histologically severe
acute cellular rejections in belatacept-treated patients as
compared with cyclosporine, very few patients on belatacept
developed DSAs (3% vs. 8% for belatacept vs. cyclosporine).
In the intent-to-treat analysis, the calculated glomerular
filtration rate (GFR) was better and continued to improve
over 3 years in the belatacept-treated patients. In fact, in the
BENEFIT trial, the belatacept-treated patients had a positive
GFR slope compared with 2ml/min/year GFR loss in the
cyclosporine-treated patients. The increase in GFR after
transplantation in the belatacept-treated patients, especially
in the BENEFIT trial, is reminiscent of the hyperfiltration
observed in the solitary kidney of the living donor. The
compensatory hyperfiltration maximizes the function of the
solitary kidney and, as has been demonstrated in kidney
donors, is not associated with glomerular injury.25,26
Furthermore, a risk-predictive model based on the outcome
at 3 years projects a 2-year increase in graft half-life with
belatacept as compared with cyclosporine in both the
BENEFIT and BENEFIT-EXT trials (Figure 4).
There are three reasons for the disparity between higher
rejection and better outcome in the belatacept-treated
patients. Recent detailed histological data show that early
acute cellular rejection unlike antibody-mediated rejection
(rare in the belatacept trial) does not impact graft survival
adversely.27 The second reason, as noted above, is the low
levels of DSAs. Rejection episodes that are not associated with
the development of DSAs are associated with good out-
come.28 DSAs are emerging as important biomarkers for
subsequent graft loss.29 This novel effect of belatacept on
DSAs has also been previously observed in experimental
models of transplantation.30 In islet and kidney transplanta-
tion in non-human primates, anti-donor antibodies were
suppressed with the use of belatacept. Although costimula-
tory blockade has no direct effect on B cells, an important
mechanism of action of belatacept is the suppression
of T helper effects on B cell. The third reason is the lack of
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Figure 1 | T-cell activation requires two signals. APC, antigen-
presenting cell; MHC, major histocompatibility complex; TCR,
T-cell receptor.
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Figure 2 |Belatacept binds with high affinity to CD86 and
Cd80 and prevents T-cell activation. APC, antigen-presenting
cell; MHC, major histocompatibility complex; TCR, T-cell receptor.
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Figure 3 | The low intensity belatacept treatment regimen in the phase III studies (BENEFIT and BENEFIT-EXT). i.v., intravenous.
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nephrotoxicity of belatacept leading to the preservation of
renal function. In addition, in the absence of CNI, the
reduction in hypertension and hyperlipidemia with belata-
cept may ultimately have a beneficial impact on cardiovas-
cular morbidities, a major cause of death with function.
Although all subgroups of patients in the trials benefited
from belatacept therapy, Epstein–Barr virus negative patients
had an unacceptable high risk for post transplant lympho-
proliferative disease (PTLD) and are not eligible for de novo
therapy with belatacept. Are all transplant recipients potentially
good candidates for belatacept? While Caucasian patients and
non-Caucasian patients (such as African Americans) as well
as recipients of kidneys from deceased donors and living
donors responded well to belatacept, some categories of
patients may not be suitable for immunosuppression with
costimulation blockade. As mentioned, Epstein–Barr virus
negative patients are at high risk of PTLD and should not be
considered for belatacept therapy. Caution should also be
used in highly sensitized patients who were not included in
the phase III trials. Memory T cells do not require costimu-
lation for full activation and so patients with an expanded
memory repertoire from alloreactive precursor T cells may be
resistant to belatacept. Finally, recipients of non-renal organ
transplants may be the greatest beneficiary of non-nephro-
toxic immunosuppression regimen. Although no trials of
belatacept have been performed in intra-thoracic organ trans-
plantation, a phase II study in liver transplantation was
terminated because of an increase in graft loss and death in
2/3 belatacept treatment arms. At present clinicians are
cautioned not to use belatacept in liver transplantation.31
One important issue in the renal function assessment of
belatacept is whether it has any direct effect on the kidney.
Is the observed difference in the GFR between belatacept
and cyclosporine a relative effect of each drug or due to
the absolute lack of nephrotoxicity and/or vasoconstriction
of belatacept? In an experimental study, 40 cynomolgus
monkeys were infused for 6 months with weekly doses of
belatacept, ranging from 10 to 50mg/kg reaching a 20-fold
increase in exposure of belatacept compared with the patients
in the phase III trials.32 At 6 months, the renal function
remained normal and stable, and kidney histology showed no
abnormalities. These observations provide convincing evi-
dence that belatacept lacks functional and histological
nephrotoxicity that clearly differentiates it from the CNIs.
Belatacept may also provide the opportunity to eliminate
both CNIs and steroids. CNI-based immunosuppression
regimens with rapid steroid withdrawal have been associated
with a high rejection rate but excellent short-term out-
comes.33,34 However, in a blinded randomized trial reported
by Woodle et al.34 after a 5-year follow-up, more patients
withdrawn from steroids developed chronic allograft ne-
phropathy. Thus, the absence of steroids from CNI-based
regimens either leads to more chronic alloimmune injury, or
the fibrogenic effects of CNIs are exaggerated by the lack of
steroids. A steroid sparing CNI-free regimen has not been
available to patients.
In a pilot study, patients treated with belatacept were
withdrawn from steroids at day 5 and were maintained on
either MMF or sirolimus.35 The control arm regimen
consisted of tacrolimus, MMF, and a similar rapid steroid
withdrawal. All patients had a short induction with
thymoglobulin. At 1 year, rejection rates were low in all
Table 3 | 3-Year outcome of the BENEFIT and BENEFIT-EXT trials
BENEFIT trial BENEFIT-EXT trial
Belatacept (n=226) CsA (n=215) Belatacept (n=174) CsA (n=179)
Patient surviving with functioning kidneys (%) 92 89 82 80
BPAR (%) 22 14 24 23
cGFR (MDRD) ml/min per 1.73m3 (s.d.) 66±27 44±24 42±25 31±22
cGFR slope over 3 years mg/min/year +1.2 2.0 0.6 1.2
Post transplant lymphoproliferative disease (%) 1a o1b 2 0
Abbreviations: BPAR, all biopsy-proven rejection; cGFR, calculated glomerular filtration rate; CsA, cyclosporine; MDRD, Modification of Diet in Renal Disease formula.
aThree patients.
bOne patient.
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Figure 4 | The projected mean graft half-life based on the
clinical profile at 3 years for the BENEFIT and BENEFIT-EXT
trials (for the approved low intensity regimen). CsA,
cyclosporine; LI, less intensive regimens.
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groups (3%, 4%, and 12% in the tacrolimus MMF arm,
belatacept sirolimus arm, and belatacept MMF arm, respec-
tively) but the belatacept arms had better GFR. This regimen,
if confirmed in a larger cohort of patients, would be an
attractive option for patients desiring elimination of both
CNIs and steroids.
Transplant professionals optimize immunosuppression
strategies through the use of drugs off label and/or not in
the registered regimen. A recent example is the combination
of tacrolimus and MMF that was embraced as the standard of
care for a decade before its actual recognition by the Food
and Drug Administration in 2009.36 Thus, it is possible that
an optimum regimen with belatacept will emerge through
similar clinical experimentation. In the interim, the clinical
progress of a second biological targeting the CD40 receptor
will be of great interest. The binding of CD40 to its ligands
is important in the activation of several immune cells,
including B cells, T cells, and macrophages. Inhibition of this
pathway was initially attempted with monoclonal antibodies
to CD40L (CD154) and resulted in prolonged graft survival
in several animal models without the requirement for CNIs.37
A clinical trial with a humanized antibody to CD40L
(5HuC8) was halted because of thromboembolic events.38 It
became apparent that CD40L is upregulated on platelets and
also has a role in stabilizing the clot, which is disrupted by
anti-CD40L monoclonal antibodies. As the CD40 receptor is
not expressed on platelets, renewed interest in inhibiting this
pathway is being tested with several novel monoclonals
targeting CD40. The most promising for transplantation is
ASKP1240, a fully human IgG4 monoclonal antibodies to
CD40. In a phase I double-blind single-dose-escalating study
in normal volunteers, ASKP1240 has been shown to be safe in
doses up to 10mg/kg.39 ASKP1240 is currently in clinical
trials in renal transplantation. Although anti-CD40 on its
own could prove to be a potent immunosuppressant, its
greatest potential could be achieved when it is combined with
belatacept resulting in dual blockade of the CD40-CD40 L
and CD28 pathways. In the seminal study in mice heart and
skin transplants, indefinite graft survival could be achieved
with this combination.40 Similar results were obtained in
non-human primate models of transplantation.41 Thus, this
dual protein therapy, if safe, could lead to potentially CNI-
free tolerogenic regimens.
CNI-FREE REGIMENS WITH SMALL MOLECULES
At present only one small molecule, tofacitinib, currently in
clinical development, offers the potential of CNI-free
regimens (Figure 5). Tofacitinib is a predominant Janus 3/2
kinase inhibitor.38 Janus kinases are cytoplasmic tyrosine
protein kinases that participate in the signaling from a broad
range of surface receptors; JAK3 is most relevant in transplant
immunology because it is linked to the g-chain, which is
part of receptors for the signaling pathway for cytokines
essential for the proliferation and activation of T and B
cells. This is not a redundant pathway, as natural mutations
of the g-chain or JAK3 lead to combined severe immunode-
ficiency. The challenge for this therapy is to induce
immunosuppression without tipping the balance to immuno-
deficiency. The importance of this pathway also suggests
that CNIs would not be required for the desired immuno-
suppression effect.
A recently reported phase 2b dose finding study utilized
tofacitinib in a more intense and a less intense regimen (a
combination of 15mg b.i.d. and 10mg b.i.d.) vs. cyclospor-
ine.42 All patients had induction with basiliximab and had
the same concomitant therapy consisting of mycophenolic
acid and steroids. At 12 months, patient and graft were
comparable in all the treatment groups, as were in rejection
episodes (all below 20%). There were very few moderate or
severe rejections (Banff II-III) with tofacitinib and no
episodes of antibody-mediated rejection. At 12 weeks,
measured GFR was significantly higher in patients who were
on tofacitinib and who also had significantly less histological
abnormalities (interstitial fibrosis and tubular atrophy) than
the cyclosporine-treated patients. However, the use of
tofacitinib, especially with the higher intensity regimen, was
associated with more infections and PTLD. Exposure
response relationships using a 2-h post dose serum
concentration of tofacitinib in the first 6 months after
transplantation showed that exposure below the median of
100 ng/ml maintained efficacy but decreased complications of
overimmunosuppression. In fact, no case of PTLD occurred
below this median concentration. Thus, the lower intensity
regimen of tofacitinib is effective and safe but therapeutic
drug monitoring may be required to ensure optimal
outcomes. An even lower dose of tofacitinib (5mg b.i.d.)
has successfully completed phase III trials for rheumatoid
arthritis and may become available for that use. The promise
of a non-nephrotoxic potent CNI, which is an alternative
agent available in a pill form, may tempt its usage off label by
transplant physicians. Without the availability of therapeutic
drug monitoring (not required for the lower dose in
rheumatoid patients), however, the use of tofacitinib in
transplantation could be challenging.
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Figure 5 |The mechanism of action of tofacitinib. JAK, Janus
kinase; STAT, signal transducer and activator of transcription.
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LONG-TERM VS. SHORT-TERM
At present belatacept is approved for use as a CNI alternative
and but is it ready for prime time? Clearly there are
challenges for the wider acceptance of this novel agent in
de novo therapy. Transplant physicians have in the past placed
the emphasis on reducing acute rejection, even though this
strategy with the current regimens has failed to improve
long-term outcome substantially. Embracing therapy with
belatacept may require wider acceptance of a novel
therapeutic paradigm for achieving better renal function,
lower DSAs, and improved cardiovascular profile with a
rejection rate that may be slightly higher than obtained with
the use of CNIs. Although it is desirable to prevent early
cellular acute rejections, they do not appear to affect long-
term outcome adversely and thus the rate of acute rejection
should not be the only measure of successful therapy.27
A better balance between preservation of renal function,
renal histology, and reduction of acute rejection needs to be
incorporated in the immunosuppressive strategies of trans-
plant professionals. The increasing concern about non-
adherence as an important cause of chronic rejection may
also enhance the attractiveness of the intravenous delivery of
belatacept that assures compliance. Of course, these benefits of
belatacept need to be balanced by the increased costs of the
drug (approximately $24,000 per year in the United States)
and its intravenous administration. Although CNIs will
continue to have an important role in immunosuppression
regimens in the near future, belatacept is now (and other novel
drugs in a few years) ready for prime time as first-line therapy
for selected patients and may offer a useful therapeutic
alternative with the promise of achieving improved outcome.
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